Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.56 -0.21 (-4.40%)
price chart
Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has been on quite a roller coaster ride in 2015. A few weeks ago, ARNA shares roared 76% higher in a single day after positive early-stage trials for an autoimmune disease treatment gave investors a ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Looks Forward To Maximizing Its ...  USMarketsDaily (blog)
Market Buzz: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Arena ...  Market News Call
Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing drugs for weight control management purposes, slumped 17% in December, based on data from S&P Capital IQ, after a rival received ...
Why Shares of Arena Pharmaceuticals, Inc. Skyrocketed Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
ARNA Stock Pops, And There's Plenty More Where That Came From
Arena's APD334 Has Real Blockbuster Potential (ARNA)  Seeking Alpha
Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Short Interest of Arena Pharmaceuticals, Inc. Drops by 0.7%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), A drop of 267,429 shares or 0.7% was seen in the short interest of Arena Pharmaceuticals, Inc.. Even as the interest dropped from 37,997,476 shares on December 31,2014 to 37,730,047 shares on January 15 ...
Belviq IMS Gains Consistent With Symphony (ARNA)
Belviq retains 40% share compared to Qsymia and Contrave, although both post better than expected numbers. Due to discounting, Arena guided to 35-45% less revenue for Q4. Whether that may be recouped in Q1 2015 may be determined by Contrave's ...
Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Related articles »  
Arena Announces Dilution - What Does It Mean? (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has announced that the company intends to conduct an offering of common stock in order to raise additional capital.
Arena Pharmaceuticals Announces Agreement to Sell Common Stock  Benzinga
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Initiates Phase 2 Clinical Trials
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has initiated the patient dosing in a Phase 2 clinical trial of ralinepag which is an oral, non-prostanoid prostacyclin (IP) receptor agonist that is intended for the treatment of pulmonary ...
Arena Pharmaceuticals Doses for Cardiovascular Study
Arena's Belviq On Track With Big Prescription Gains (ARNA)
Belviq regains a 50% share; rival Qsymia has much lower totals than last year, while Contrave launch complete stalls. Eisai initiated a new marketing initiative to counter Takeda's Direct Save program; its impact may be felt as soon as next week.
Forget Pills! Could This Device Put an End to Obesity in America?  Motley Fool